Benign Brain and Central Nervous System Tumors by A

Total Page:16

File Type:pdf, Size:1020Kb

Benign Brain and Central Nervous System Tumors by A GCCR Register Georgia Comprehensive Cancer Registry Spring 2004 Benign Brain and Central Nervous System Tumors By A. Rana Bayakly, GCCR Director Based on NAACCR 2004 Implementation Guidelines www.naaccr.org Benign brain and central nervous program) to collect both benign and Casefinding- Hospital casefinding system tumors (CNS) are deadly because of malignant CNS tumors. list should now include the following ICD- their location and their impact on the brain. Commission on Cancer (COC) and 9-CM codes to identify all the potential Although often removable, they may result the Surveillance Epidemiology and End cases: in death, paralysis, blindness and other Results (SEER) added benign CNS tumors • 225.0 Benign neoplasm of brain brain damage. to their case definition as of January 1, • 225.1 Benign neoplasm of cranial Malignant CNS tumors are the 2004. Georgia reporting mandate was nerves second most common cancer in children, changed to add benign CNS tumors to the • 225.2 Benign neoplasm of cerebral accounting for 23% of all childhood cancers reportable list for all cases diagnosed on meninges; cerebral meningioma death in Georgia. They also are the third January 1, 2004 and later. • 225.3 Benign neoplasm of spinal leading cancer cause of death in young In Georgia any tumor diagnosed cord, cauda equina adults aged 15-34 in the United States and on January 1, 2004 or later with a behavior • 225.4 Benign neoplasm of spinal Georgia. code of ‘0’ or ‘1’ is reportable for the meninges; spinal meningioma The number of benign CNS tumors following Site Codes (ICD-O-3): • 225.8 Benign neoplasm of other diagnosed in Georgia each year is unknown, Meninges C70.0 – C70.9; Brain C71.0 – specified sites of nervous system but is thought to be similar to the number of C71.9; Spinal Cord, cranial nerves, and • 225.9 Benign neoplasm of nervous malignant CNS tumors. other parts of the Central nervous System system, part unspecified Meningioma, a “benign” brain C72.0 – C72.9; Pituitary gland C75.1; • 227.3 Benign neoplasm of pituitary, tumor that accounts for one-fourth to one- Craniopharyngeal duct C75.2; and Pineal craniopharyngeal duct, craniobuccal third of all brain cancers, is more deadly gland C75.3. Histology codes are based on pouch, hypophysis, Rathke’s pouch, than breast cancer. Thirty-one percent the ICD-O-3 book. Juvenile astrocytomas sella turcica (31%) of patients with meningioma die should continue to be reported as 9421/3. 227.4 Benign neoplasm of pineal within five years, compared to only sixteen Laterality- beginning with • gland, pineal body percent (16%) for breast cancer. malignant and benign tumors diagnosed in Improvements in understanding 2004, the following sites require a laterality • 237.0 Neoplasm of uncertain the disease and its course, as well as code of 1-4 or 9: behavior of pituitary gland and craniopharyngeal duct advances in treatment, depend on accurate • Cerebral meninges, NOS C70.0 • 237.1 Neoplasm of uncertain data collection. There are many reasons to • Cerebrum C71.0 behavior of pineal gland collect data on benign tumors: • Frontal lobe C71.1 • 237.5 Neoplasm of uncertain • Approximately half of all patients • Temporal lobe C71.2 behavior of brain and spinal cord diagnosed with brain tumors are • Parietal lobe C71.3 • 237.6 Neoplasm of uncertain currently excluded from data collection • Occipital lobe C71.4 behavior of meninges: NOS, cerebral, efforts; it is not possible to monitor the • Olfactory nerve C72.2 impact of this condition on Georgia spinal • Optic nerve C72.3 citizens. • 237.70 Neurofibromatosis, • Acoustic nerve C72.4 • Some benign tumors become malignant Unspecified von Recklinghausen’s • Cranial nerve, NOS C72.5 over time; Disease The research community has • Due to their location and • 237.71* Neurofibromatosis, Type One indicated that the location and laterality for responsiveness to treatment, benign von Recklinghausen’s Disease primary CNS tumors is of significant • 237.72 Neurofibromatosis, Type Two and malignant brain tumors have interest in determining causation and similar prognoses; von Recklinghausen’s Disease assessing the impact on quality of life. • Since causes of brain tumors are not • 237.9 Neoplasm of uncertain Grade-The World Health behavior of other and unspecified parts well understood, studying the etiology Organization (WHO) grade should be of nervous system; cranial nerves of benign brain tumors will improve recorded in Site Specific Factor 1 of the CS our understanding of malignant tumors; It is estimated that reporting system, histological grade will continue to benign and CNS tumors are similar to the The Benign Brain Tumor Cancer be collected as the morphology sixth digit malignant CNS tumors approximately 1% Registries Amendment Act was signed by ‘Grade’. the President in October 2002. Public Law of the total caseload at the central registry. Sequence Number- primary non- However the hospital caseload will be 107-260 requires the collection of benign malignant tumors diagnosed on or after dependent on the type of reporting facility, and central nervous system tumors by the January 1, 2004 should be sequenced in the National Program of Cancer Registries hospitals with small or no neurology service range of 60-87. will likely experience a minimal increase, (NPCR). This law requires all cancer Site/Histology Validation List is however hospitals with a large neurology registries authorized by the Public Law and available in the ICD-O-3 primary brain and funded by the federal government (NPCR service will likely experience a larger CNS site histology list. increase. Reporting facilities need (cont.) Benign CNS Tumors (cont.) The GCCR is planning to conduct directed to your regional coordinator or you training on reporting benign brain and CNS may go to the Ask NAACCR web site at to review the following casefinding sources tumors during our Spring Training April www.naaccr.org/Standards/AskNAACCR.h for identifying these cases: Pathology, 28-30, 2004. You can also find training tml. A panel, including representatives cytology; disease indices; surgery logs; materials on the NAACCR website at from each standard setting organization will diagnostic imaging; radiation oncology; www.naaccr.org or on SEER training web review each question and provide an neurology clinics; medical oncology and site at www.training.seer.cancer.gov. answer. autopsy reports. Inquires regarding the collection of the benign and CNS tumors should be Welcome Wagon The cancer registry profession has Teri’s husband Perry is a police officer in their town and retired 2 a new recruit in its ranks. Teri Carter of Supervisor with the City of LaGrange years ago after 25 years as Lieutenant over LaGrange accepted the offer as the new Water Department and they are planning a the Detective Division. Teri stated that her cancer registrar for West Georgia Health trip to Canada next year to celebrate their mother showed her “that no obstacle is Systems. 30th wedding anniversary. insurmountable if you believe in yourself.” Teri has lived in LaGrange for 46 More immediate celebrations That is sound wisdom for all years, her entire life. A former middle include their only daughter’s wedding cancer registrars and we all welcome Teri school teacher, she has worked in the which will take place in June. Carter to the cancer registry profession. medical field for 5 years coming from Teri enjoys reading, cross-stitch Betty Gentry, RHIT, CTR LaGrange Internal Medicine as a Certified and painting in her spare time. When asked Central Regional Coordinator Medical Assistant before moving to West whom she admired most, she said her Macon Georgia Health System. mother. Her mother was the first female Blue Ribbon Award During the recent CDC/NPCR a very nice conference room reserved for was responsible for all the data being audit, Phoebe Putney Memorial Hospital in the auditor’s use and had all the requested available for the audit. Albany and South Georgia Medical Center records available for their review. As the Southwest Regional in Valdosta were two of the nine hospitals The Pathology Department of both Coordinator, I was very proud of these selected to be part of the audit process. hospitals had hard copies of the path reports hospitals and along with GCCR, GCCS at The Registrars and staff at both of available rather than electronic files, which Emory, and CDC would like to thank these facilities deserve a blue ribbon for made the review much easier. The Medical Phoebe Putney Memorial Hospital and their efforts in having everything in place Records Department at Phoebe retrieved South Georgia Medical Center and tell them for the auditors, which made the audit records from storage for the audit and how much we appreciate their work. process run vary smooth and efficiently. electronic medical records were printed out The auditors commented on how at South Georgia. Carol Crosby, CTR impressed they were with both of these The Registry staff at both facilities Southwest Regional Coordinator facilities and how much they appreciated coordinated the requests of documents and Albany their cooperation and hospitality. Both had HIPAA Corner Adapted from: Hiatt, RA. HIPAA: The End of Epidemiology, or a New Social Contract? Epidemiology. 2003;14:637-639. HIPAA was not intended to interfere with public health and The data collection effort by the AAMC is a systematic and medical research. However, what if there are genuinely deleterious constructive effort to document the HIPAA-related problems for effects? One positive step we can all take is to read and understand research that will be essential to future decision-making. It will help the new privacy regulations. We might need to press for changes in show the burden of compliance, and it could uncover new issues that the regulation. In fact, there are already mechanisms in place to were not considered in the formulation of the current Rule.
Recommended publications
  • INTRINSIC FACTORS in the ETIOLOGY of NEOPLASMS' It Is
    INTRINSIC FACTORS IN THE ETIOLOGY OF NEOPLASMS' CARL V. WELLER, MS., M.D. (From the Department of Pathology, University of Michigan) It is as true as it is trite that the cause of disease is never a single factor. Two elements always enter into etiology. One of these is inherent in the germ plasm of the individual; the other brought to bear upon the organism from beyond the confines of the germinal elements from which it has devel- oped. Better than internal and external, endogenous and exogenous, or con- stitutional and environmental, to designate these two groups of factors, are the terms intrinsic and extrinsic. Practical experience directs us to seek the relative importance of intrinsic and extrinsic factors whenever the causation of disease is studied, and we find that the two ingredients may be combined in every possible proportion. At one end of the series are diseases such as deaf mutism, transmitted as a simple recessive, in which the intrinsic element almost crowds out all other considerations. In the recessively sex-linked hemophilia, again the intrinsic element is so prominent that we see at once the mendelian significance of the process, although the bleeder may not be made known until the extrinsic factor, trauma, opens his blood vessels. The asthenic, dolichomorphic bodily configuration, which marks the phthisical habitus, is a familial character and therefore intrinsic, but it conditions infection by the tubercle bacillus in such a way as to give it serious or even lethal possibilities. When we consider syphilis, we find that the Treponema is no respecter of genetic constitution, yet sex and race may modify the character of the disease.
    [Show full text]
  • Brain Tumors
    BRAIN TUMORS What kinds of brain tumors affect pets? Brain tumors occur relatively often in dogs and cats. The most common type of brain tumor is a meningioma, which originates from the layer surrounding the brain, called the meninges. Meningiomas are slow-growing benign tumors that are often present for months to years before clinical signs appear. Other common types in- clude glial cell tumors, which originate in the brain tissue, and choroid plexus tumors, which originate from the tissue in the brain that produces spinal fluid. Tumors in structures around the brain (like nasal tumors, skull tumors, and pituitary tumors) may also com- press the brain. Lymphoma is a type of cancer that can affect multiple parts of the brain and spine. What are the symptoms? Symptoms vary and depend on the size and location of the tumor. Common signs include changes in behavior, circling or pacing, staring into space, getting stuck in corners, and seizures. Other signs can include weakness, lack of alertness, difficulty eating or swallowing, and problems with the “vestibular system,” or system of bal- ance, such as lack of coordination, head tilt, leaning/circling/falling to one side, and abnormal eye movements. How are brain tumors diagnosed? An MRI scan produces an image of the brain that’s more detailed than a CT scan or x-ray and can identify a tumor. Often the appearance of the tumor on MRI suggests the type of tumor (i.e. meningioma vs lymphoma). However, a biopsy of the tumor is required to give a definitive diagnosis. In some cases, spinal fluid is collected to help diagnose lymphoma.
    [Show full text]
  • Updates in Molecular Pathology of Central Nervous System Gliomas in Adults
    UPDATES IN ONCOLOGY: PART 2 Updates in Molecular Pathology of Central Nervous System Gliomas in Adults MICHAEL PUNSONI, MD; JOHN E. DONAHUE, MD; HEINRICH D. ELINZANO, MD; TIMOTHY KINSELLA, MD 17 19 EN ABSTRACT Epidemiology Central nervous system (CNS) tumors are a heteroge- The incidence of CNS malignancies has been increasing. neous group of neoplasms divided into two broad cate- Most commonly, CNS tumors arise from glial cells, partic- gories, glial and non-glial. Non-glial tumors are derived ularly astrocytes and oligodendrocytes. Gliomas account from such diverse structures as the pineal gland, menin- for approximately 77% of primary malignant brain tumors ges, germ cells, and hematopoietic cells, as well as metas- (3). Most patients present between the fifth and seventh tases. Primary glial neoplasms, or those which originate decade of life. High-grade tumors are more common than from astrocytes, oligodendrocytes, or ependymal cells, low-grade and present a high risk of morbidity and mortal- include astrocytomas, oligodendrogliomas, ependymo- ity. The World Health Organization (WHO) in 2000 formu- mas, and mixed gliomas. Each entity has a unique mor- lated a classification system based on histologic findings phology and pattern of biologic behavior which portends that is used to stratify brain tumors into prognostic grades. a distinct prognosis and outcome. Individual outcomes High-grade gliomas (WHO grade III and IV) are most com- show some variability based on tumor location and age of monly seen in middle-aged to older adults, while grade II symptom onset; however, the underlying aggressiveness astrocytomas mainly affect younger adults. Management for of the tumor often dictates the time course of the disease.
    [Show full text]
  • 797 Circulating Tumor DNA and Circulating Tumor Cells for Cancer
    Medical Policy Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) Table of Contents • Policy: Commercial • Coding Information • Information Pertaining to All Policies • Policy: Medicare • Description • References • Authorization Information • Policy History • Endnotes Policy Number: 797 BCBSA Reference Number: 2.04.141 Related Policies Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer, #336 Policy1 Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Plasma-based comprehensive somatic genomic profiling testing (CGP) using Guardant360® for patients with Stage IIIB/IV non-small cell lung cancer (NSCLC) is considered MEDICALLY NECESSARY when the following criteria have been met: Diagnosis: • When tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP or invasive biopsy is medically contraindicated), AND • When prior results for ALL of the following tests are not available: o EGFR single nucleotide variants (SNVs) and insertions and deletions (indels) o ALK and ROS1 rearrangements o PDL1 expression. Progression: • Patients progressing on or after chemotherapy or immunotherapy who have never been tested for EGFR SNVs and indels, and ALK and ROS1 rearrangements, and for whom tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP), OR • For patients progressing on EGFR tyrosine kinase inhibitors (TKIs). If no genetic alteration is detected by Guardant360®, or if circulating tumor DNA (ctDNA) is insufficient/not detected, tissue-based genotyping should be considered. Other plasma-based CGP tests are considered INVESTIGATIONAL. CGP and the use of circulating tumor DNA is considered INVESTIGATIONAL for all other indications. 1 The use of circulating tumor cells is considered INVESTIGATIONAL for all indications.
    [Show full text]
  • Neuro-Oncology
    Neuro-Oncology Neuro-Oncology 17:iv1–iv62, 2015. doi:10.1093/neuonc/nov189 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 Quinn T. Ostrom M.A., M.P.H.1,2*, Haley Gittleman M.S.1,2*, Jordonna Fulop R.N.1, Max Liu3, Rachel Blanda4, Courtney Kromer B.A.5, Yingli Wolinsky Ph.D., M.B.A.1,2, Carol Kruchko B.A.2, and Jill S. Barnholtz-Sloan Ph.D.1,2 1Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH USA 2Central Brain Tumor Registry of the United States, Hinsdale, IL USA 3Solon High School, Solon, OH USA 4Georgetown University, Washington D.C. USA 5Case Western Reserve University School of Medicine, Cleveland, OH USA *Contributed equally to this Report. Introduction for collection of central (state) cancer data as mandated in 1992 by Public Law 102-515, the Cancer Registries Amendment The objective of the CBTRUS Statistical Report: Primary Brain and Act.2 This mandate was expanded to include non-malignant Central Nervous System Tumors Diagnosed in the United States brain tumors diagnosed in 2004 and later with the 2002 in 2008-2012 is to provide a comprehensive summary of the passage of Public Law 107–260.3 CBTRUS researchers combine current descriptive epidemiology of primary brain and central the NPCR data with data from the SEER program4 of the NCI, nervous system (CNS) tumors in the United States (US) popula- which was established for national cancer surveillance in the tion. CBTRUS obtained the latest available data on all newly early 1970s.
    [Show full text]
  • Connections Between Warburg's and Szentgyorgyi's Approach About The
    Research iMedPub Journals Journal of Neoplasm 2017 http://www.imedpub.com/ ISSN 2576-3903 Vol.1 No.2:8 DOI: 10.217672576-3903.100008 Connections between Warburg’s and Szentgyorgyi’s Approach about the Causes of Cancer Szigeti GP1, Szasz O2 and Hegyi G3 1Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Hungary 2Department of Biotechnics, St. Istvan University, Hungary 3Department of Complementary and Alternative Medicine, University of Pecs, Hungary Corresponding author: Gabriella Hegyi, Department of Complementary and Alternative Medicine, University of Pecs, Hungary, Tel: +36 30 922-5347; E-mail: [email protected] Rec date: November 30, 2016; Acc date: December 26, 2016; Pub date: December 30, 2016 Citation: Szigeti GP, Szasz O, Hegyi G. Connections Between Warburg’s and Szentgyorgyi’s Approach About Causes of Cancer. J Neoplasm. 2017, 1: 2. to the environmental, diet and habit origins of malignant Abstract diseases [21-23]. Most widely, cancer is believed to be an abnormal tissue Numerous theories and hypotheses are published about triggered by a gene mutation. However, the proto-oncogene the causes of cancer and its hallmarks. Two remarkable and the oncogene appear not only in cancerous cases [24], but principles were established and debated for a long time. with pregnancy [25], with embryogenesis [26,27], with the The first is the Warburg-effect, which based on healing of wounds [28] and with the synthesis of growth mitochondrial dysfunction, connected to the intensive factors [29]. Oncogenes show a great variety of anti-apoptotic metabolic activity of the malignancy. The other is the functions with the cells taking part in the wound-healing [30].
    [Show full text]
  • Injury and Cancer
    Case Western Reserve Law Review Volume 5 Issue 2 Article 4 1954 Injury and Cancer Lester Adelson Follow this and additional works at: https://scholarlycommons.law.case.edu/caselrev Part of the Law Commons Recommended Citation Lester Adelson, Injury and Cancer, 5 W. Rsrv. L. Rev. 150 (1954) Available at: https://scholarlycommons.law.case.edu/caselrev/vol5/iss2/4 This Article is brought to you for free and open access by the Student Journals at Case Western Reserve University School of Law Scholarly Commons. It has been accepted for inclusion in Case Western Reserve Law Review by an authorized administrator of Case Western Reserve University School of Law Scholarly Commons. [Winter Injury and Cancer by Lester Adelson, M.D. WITH LEGAL ANNOTATIONS BY OLIVER SCHROEDER, JR.* INTRODUCTION THE WORD "cancer" is one which is charged with emotion and fear, carrying with it implications of prolonged disability and slow, certain and painful death.' In considering and discussing the subject of cancer, diffi- culties frequently arise, not because not enough is known, but because so much is known that-is incorrect and untrue. A vast fund of misinformation and false information mis- leads the unwary stranger THE AUTHOR (A.B., 1935, Harvard Univer- and the uncritical observer. sity; M.D., 1939, Tufts College Medical School) is Chief Deputy Coroner and Patholo- Cancer is the second gist at the Coroner's Office, Cuyahoga County, leading cause of death, and Ohio, and Assistant Professor of Legal Medi- problems which arise in cine at the School of Medicine of Western Reserve University. connection with it are seen frequently.
    [Show full text]
  • Hematopoietic and Lymphoid Neoplasm Coding Manual
    Hematopoietic and Lymphoid Neoplasm Coding Manual Effective with Cases Diagnosed 1/1/2010 and Forward Published August 2021 Editors: Jennifer Ruhl, MSHCA, RHIT, CCS, CTR, NCI SEER Margaret (Peggy) Adamo, BS, AAS, RHIT, CTR, NCI SEER Lois Dickie, CTR, NCI SEER Serban Negoita, MD, PhD, CTR, NCI SEER Suggested citation: Ruhl J, Adamo M, Dickie L., Negoita, S. (August 2021). Hematopoietic and Lymphoid Neoplasm Coding Manual. National Cancer Institute, Bethesda, MD, 2021. Hematopoietic and Lymphoid Neoplasm Coding Manual 1 In Appreciation NCI SEER gratefully acknowledges the dedicated work of Drs, Charles Platz and Graca Dores since the inception of the Hematopoietic project. They continue to provide support. We deeply appreciate their willingness to serve as advisors for the rules within this manual. The quality of this Hematopoietic project is directly related to their commitment. NCI SEER would also like to acknowledge the following individuals who provided input on the manual and/or the database. Their contributions are greatly appreciated. • Carolyn Callaghan, CTR (SEER Seattle Registry) • Tiffany Janes, CTR (SEER Seattle Registry) We would also like to give a special thanks to the following individuals at Information Management Services, Inc. (IMS) who provide us with document support and web development. • Suzanne Adams, BS, CTR • Ginger Carter, BA • Sean Brennan, BS • Paul Stephenson, BS • Jacob Tomlinson, BS Hematopoietic and Lymphoid Neoplasm Coding Manual 2 Dedication The Hematopoietic and Lymphoid Neoplasm Coding Manual (Heme manual) and the companion Hematopoietic and Lymphoid Neoplasm Database (Heme DB) are dedicated to the hard-working cancer registrars across the world who meticulously identify, abstract, and code cancer data.
    [Show full text]
  • Cancer Risk Assessment and Cancer Prevention: Promises and Challenges
    CommentaryCancer Prevention Research Cancer Risk Assessment and Cancer Prevention: Promises and Challenges Brian J. Reid “Acquired genetic lability permits stepwise selection of variant cancer itself, but morphologic assessment may be limited in its sublines and underlies tumor progression” (1). ability to distinguish asymptomatic indolent conditions from Despite intense efforts to cure cancers through advances in those that will progress to advanced malignancies and death staging, surgery, chemo- and radiation therapy, treatment of (3–5, 13). Examining cancer from an evolutionary perspective most advanced, symptomatic epithelial malignancies con- can open new approaches for cancer risk assessment, diagnosis, tinues to be challenging, and age-adjusted cancer mortality therapy and prevention. The evolution of multicellular organ- in the United States has decreased by only 5%since 1950 isms has been accompanied by constraint of cellular evolution, (2). The clinical course of treated cancer patients all too often and cancer represents a breakdown of the mechanisms that culminates in relapse and death. Ironically, growing evidence suppress cellular evolution. Cairns hypothesized that the archi- also suggests that many patients with premalignancy or even tecture of proliferating epithelial tissues would suppress tumor malignancy follow benign courses and die far more often of formation by restricting and sequestering stem cells in epithe- non-cancer causes than of cancer (3–5). These paradoxical phe- lial proliferative units, for example, at the base of intestinal nomena form the dilemma of early detection-underdetection crypts (14). Opportunities for competition between variants of life-threatening early disease and overdetection of indolent that might arise would be restrained by shedding differentiated early disease.
    [Show full text]
  • A Circulating Tumor DNA
    Journal of Tumor Research Editorial A Circulating Tumor DNA Loay Parrella* Laboratory of Cellular and Molecular Endocrinology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy EDITORIAL NOTE Fragmentation of this length can be indicative of apoptotic DNA fragmentation, suggesting that necrobiosis is also the first Circulating Tumor DNA (CTDNA) is tumor-derived fragmented technique of CTDNA unleash. The fragmentation of CFDNA is DNA within the blood that's not related to cells. CTDNA altered with in the plasma of cancer patients. The main charm of mustn't be confused with non-cellular DNA (CFDNA), a CTDNA analysis is that it's extracted in an exceedingly broader term that describes DNA that's freely current within the noninvasive manner through blood assortment. Acquisition of blood, however isn't essentially of neoplasm origin. As a result of CFDNA or CTDNA usually needs assortment of roughly 3mL CTDNA could replicate the complete neoplasm ordination, its of blood into EDTA- coated tubes. The employment of EDTA is gained traction for its potential clinical utility; “liquid biopsies” vital to cut back curdling of blood. The plasma and humor within the type of blood attracts is also taken at numerous time fractions of blood are often separated through an action step. points to observe neoplasm progression throughout the CTDNA or CFDNA are often later extracted from these treatment program. CTDNA originates directly from the Tumor fractions. Though humor tends to possess larger levels of or from Current Tumor Cells (CTCs), that describes viable, CFDNA, this can be primarily attributed to DNA from intact neoplasm cells that shed from primary tumors and enter lymphocytes.
    [Show full text]
  • Neoplasm, Lesion Or Infection
    National Imaging Associates, Inc. Clinical Guideline Original Date: July 2015 SPINE SURGERY OTHER: NEOPLASM, Page 1 of 3 LESION OR INFECTION (ALL REGIONS) CPT Codes: 63265, 63266, 63267, 63268, 63270, Last Review Date: 63271, 63272, 63273, 63275, 63276, 63277, 63278, 63280, 63281, 63282, 63283, 63285, 63286, 63287, 63290, 63295. 63290, 63295, 22590, 22595, 22600, 22610, 22612, 22614.22630, 22632, 22633, 22634, 22554, 22556, 22558, 22585, 22532, 22533, 22534 Guideline Number: NIA_CG_309 Last Revised Date: Responsible Department: Implementation Date: September 2015 Clinical Operations OVERVIEW: Significant spinal cord or nerve root compression due to tumor, lesion or infection may require surgical intervention. All operative interventions must be based on a positive correlation with clinical findings, the natural history of the disease, the clinical course, and diagnostic tests or imaging results. INDICATIONS: A. FUSION SURGERY (ANY REGION) FOR THE TREATMENT OF SPINAL NEOPLASM, LESION OR INFECTION. Significant spinal cord or nerve root compression due to tumor or infection may require decompression of the cord / roots and fusion of the involved levels. Fusion is reserved for cases wherein the structural integrity of the spine has been compromised by the disease process or the surgical intervention needed to address the disease process. The following criteria must be met for urgent intervention: Positive Clinical Findings of Myelopathy with evidence of progressive neurologic deficits consistent with worsening spinal cord compression due to tumor or infection— immediate surgical evaluation is indicated. Symptoms may include any of the following: . upper extremity weakness . unsteady gait related to myelopathy/balance or generalized lower extremity weakness . disturbance with coordination . hyperreflexia . Hoffmann sign .
    [Show full text]
  • Brain Invasion in Meningioma—A Prognostic Potential Worth Exploring
    cancers Review Brain Invasion in Meningioma—A Prognostic Potential Worth Exploring Felix Behling 1,2,* , Johann-Martin Hempel 2,3 and Jens Schittenhelm 2,4 1 Department of Neurosurgery, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany 2 Center for CNS Tumors, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany; [email protected] (J.-M.H.); [email protected] (J.S.) 3 Department of Diagnostic and Interventional Neuroradiology, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany 4 Department of Neuropathology, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany * Correspondence: [email protected] Simple Summary: Meningiomas are benign tumors of the meninges and represent the most common primary brain tumor. Most tumors can be cured by surgical excision or stabilized by radiation therapy. However, recurrent cases are difficult to treat and alternatives to surgery and radiation are lacking. Therefore, a reliable prognostic marker is important for early identification of patients at risk. The presence of infiltrative growth of meningioma cells into central nervous system tissue has been identified as a negative prognostic factor and was therefore included in the latest WHO classification for CNS tumors. Since then, the clinical impact of CNS invasion has been questioned by different retrospective studies and its removal from the WHO classification has been suggested. Citation: Behling, F.; Hempel, J.-M.; There may be several reasons for the emergence of conflicting results on this matter, which are Schittenhelm, J. Brain Invasion in discussed in this review together with the potential and future perspectives of the role of CNS Meningioma—A Prognostic Potential invasion in meningiomas.
    [Show full text]